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Abstract: Epidemiologic studies have linked urinary oxalate excretion to risk of chronic kidney
disease (CKD) progression and end-stage renal disease. We aimed to investigate whether urinary
oxalate, in stable kidney transplant recipients (KTR), is prospectively associated with risk of graft
failure. In secondary analyses we evaluated the association with post-transplantation diabetes
mellitus, all-cause mortality and specific causes of death. Oxalate excretion was measured in 24-h
urine collection samples in a cohort of 683 KTR with a functioning allograft ≥1 year. Mean eGFR was
52 ± 20 mL/min/1.73 m2. Median (interquartile range) urinary oxalate excretion was 505 (347–732)
µmol/24-h in women and 519 (396–736)µmol/24-h in men (p = 0.08), with 302 patients (44% of the study
population) above normal limits (hyperoxaluria). A consistent and independent inverse association
was found with all-cause mortality (HR 0.77, 95% CI 0.63–0.94, p = 0.01). Cause-specific survival
analyses showed that this association was mainly driven by an inverse association with mortality
due to infection (HR 0.56, 95% CI 0.38–0.83, p = 0.004), which remained materially unchanged after
performing sensitivity analyses. Twenty-four-hour urinary oxalate excretion did not associate with
risk of graft failure, post-transplant diabetes mellitus, cardiovascular mortality, mortality due to
malignancies or mortality due to miscellaneous causes. In conclusion, in KTR, 24-h urinary oxalate
excretion is elevated in 44% of KTR and inversely associated with mortality due to infectious causes.
Keywords: oxalate; hyperoxaluria; kidney transplant recipients; graft failure; post-transplantation
diabetes mellitus; all-cause mortality; cardiovascular mortality; infectious mortality
1. Introduction
Kidney transplantation is considered the gold standard treatment for end-stage renal disease
(ESRD) [1,2]. Short-term survival of kidney transplant recipients (KTR) has improved markedly
in the past decades [3,4]. Although a better understanding of modifiable risk factors has been
achieved over the recent years [5,6], patients perceive the ever existing threat of premature graft
failure (GF) as most compelling, and would like to know whether factors such as lifestyle and diet can
contribute to prevention of it [7,8]. Another factor of interest influencing long-term KTR survival is
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post-transplantation diabetes mellitus (PTDM), which has become increasingly common and may affect
patient and graft survival [9]. Further, an increased risk of premature mortality, in particular, increased
risk for premature death from cardiovascular and infectious causes remain significant problems in
the post-transplantation setting. In KTR, conventional risk factors for cardiovascular mortality are
abundantly present, such as hypertension, diabetes mellitus and dyslipidemia. On top of that, KTR
had pre-existent renal diseases, which additionally increases the cardiovascular risk [10]. Mortality
due to infection is significantly higher in KTR than in the general population due to multiple reasons,
to which immunosuppressive therapy is a large contributing factor [11]. Furthermore, KTR are at a
two to threefold higher risk of cancer-related mortality compared to the general population [12].
Although different mechanisms underlying these long-term complications of kidney
transplantation have been found, substantial unknown mechanisms particular to the post-kidney
transplantation setting remain to be identified in order to provide rationale for the markedly high risk
of premature mortality in KTR [13]. A recent prospective cohort study in 3123 patients with chronic
kidney disease (CKD) stages 2 to 4, found urinary oxalate as a potential risk factor for progression
of CKD [14]. In the post-kidney transplantation setting, the study of oxalate remains overlooked.
Whether urinary oxalate (reference value ≤455 µmol/24-h) [15] may be prospectively associated with
adverse outcomes in KTR remains unknown.
The current study aims to assess the potential association of urinary oxalate excretion with adverse
long-term outcomes in a large cohort of extensively phenotyped KTR with a functioning graft ≥1 year.
For this purpose, the prospective associations of 24-h urinary oxalate excretion with GF, PTDM, and
overall and cause-specific mortality were systematically investigated.
2. Experimental Section
2.1. Study Design and Population
This is a single-center prospective cohort study, initiated in 2008 on with follow-up of endpoints
until 2015. KTR with a functioning allograft for at least one year or more who visited the outpatient
clinic of the University Medical Center Groningen (Groningen, The Netherlands) between November
2008 and March 2011. Exclusion criteria were no known or apparent systemic illnesses, insufficient
knowledge of the Dutch language and history of drug or alcohol addiction according to their patient
files. KTR received anti-hypertensive and standard maintenance immunosuppressive therapy. Of the
817 invited KTR, 706 (87%) signed informed consent. Patients missing 24-h urinary oxalate excretion
were excluded from the analyses, resulting in 683 KTR eligible for statistical analyses. The study
was conducted in concordance with the guidelines formulated in the Declaration of Helsinki and
Istanbul, and approved by the Institutional Review Board of the UMCG (METc 2008/186) [16]. The
continuous surveillance system according to the American Society of Transplantation was followed for
the correct collection of data [17]. When status of patients was unknown, the referring nephrologist or
general practitioners were contacted in order to obtain the missing information. There was no loss due
to follow-up.
2.2. Study Endpoints
The primary endpoint of this study is death-censored GF. Secondary endpoints are PTDM,
all-cause mortality and cause-specific mortality. GF occurrence in this study is defined as ESRD
requiring re-transplantation or return to dialysis. A subject was considered to have developed PTDM
when the fasting plasma glucose exceeded 7 mmol/L, the HbA1c exceeded 6.5% or use of antidiabetics
after transplantation as registered in the patient database [18,19]. Among specific causes of death, we
studied cardiovascular mortality, death from infection, death from malignancies, and other causes
of death (miscellaneous). Cardiovascular mortality is defined as mortality caused by cardiovascular
pathophysiology, coded by ICD-10 codes I10-I52. This information was obtained from linking the
patient number to the database of the Central Bureau of Statistics and then, by physicians, reported
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mortality cause. Infectious mortality and mortality due to malignancies were defined as mortality
caused by infectious causes or malignant causes. Miscellaneous causes of mortality have been defined
as other causes of death besides the previously described outcomes.
2.3. Baseline Measurements and Definitions
At the outpatient clinic, baseline data was gathered according to a strict and detailed protocol
described previously [20]. Anthropometrics were obtained without shoes and heavy garments. Systolic
and diastolic blood pressures (SBP and DBP) were measured by means of an automatic device (Philips
Suresign VS2+, Andover, MA, USA) according to a standard clinical protocol [16]. Mean arterial
pressure (MAP) was automatically calculated by (SBP + DBP × 2)/3. History of cardiovascular disease
was searched for in the patient files under ICD-10 code Z86.7.
Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared
(kg/m2) [21]. Estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology
Collaboration (CKD-EPI) creatinine equation as shown in Formula (S1) [22].
2.4. Assesments of Physical Activity and Dietary Intake
Physical activity was quantified using the Short Questionnaire to Assess Health-enhancing
physical activity (SQUASH). Activity was expressed in intensity multiplied by the amount of hours [23].
Dietary intake was assessed using a semi-quantitative Food Frequency Questionnaire (FFQ) [24,25]. To
obtain the energy of a certain product, the Dutch Food Composition Table of 2016 was used [26]. Micro
and macronutrients were adjusted for total energy intake (kCal), because of the potential of correlation
and confounding [27].
2.5. Laboratory Measurements
For the collection of 24-h urine samples, the patients were asked to start the collection the
day prior to their visit to the outpatient clinic. Collection was done in concordance with a strict
protocol, i.e., discarding the first morning urine, collecting the subsequent in 24 h including the next
morning’s urine [16]. Subsequently, urine samples for oxalate analysis were acidified and stored at
−80 ◦C. Urine oxalate analysis was performed using a validated ion-exchange chromatography assay
with conductivity detection (Metrohm, Herisau, Switzerland). Inter-assay precision was monitored
using three urine pool samples. Inter-assay precision was 8.2% at 0.17 mmol/L, 7.0% at 0.38 mmol/L
and 9.0% at 0.52 mmol/L. Comparison of this method with a routine laboratory GC-MS method
showed no systemic difference and no proportional difference. Reverse-phase high performance liquid
chromatography (HPLC) was used to measure urinary thiosulfate [28].
2.6. Statistical Analyses
Data was analyzed using IBM SPSS version 23.0 (SPSS Inc., Chicago, IL, USA); Stata version 14.0
(StataCorp., College Station, TX, USA), GraphPad Prism version 7.02 (GraphPad Software, La Jolla,
CA, USA), and Rstudio version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria). A
two-sided p < 0.05 was considered significant in all following analyses.
Normally distributed variables are expressed as mean ± standard deviation (SD), skewed data as
medians (Interquartile range (IQR)), and categorical data as given number and percentage. Baseline
characteristics were described for the overall population and by sex-stratified tertiles of 24-h urinary
oxalate excretion. Data are presented in tertiles to allow for assessment of linearity of cross-sectional
associations of 24-h urinary oxalate excretion with other variables. Sex-stratified tertiles were created
by first separately distributing all female subjects according to tertiles and distributing all male
subjects according to tertiles, and thereafter combining the tertiles of females and males. We generated
sex-specific tertiles because of differences between women and men in oxalate excretion [29–32].
Analyses of difference in baseline characteristics across sex-stratified tertiles of 24-h urinary oxalate
excretion were tested by ANOVA for normally distributed continuous variables, Kruskal-Wallis
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for skewed continuous variables and χ2 test for categorical data. Sex-stratified tertiles of 24-h
oxalate excretion were tested for associations with outcomes by Kaplan-Meier analysis, including the
log-rank test.
Linear regression analyses were performed to investigate the association of baseline characteristics
with 24-h urinary oxalate excretion. Normality was assessed by means of a p–p plot, and a natural log
transformation was performed when appropriate. Homoscedasticity was controlled in a scatterplot.
Cox regression analyses were used to investigate the association of 24-h urinary oxalate with
primary and secondary outcomes. Model 1 of the Cox proportional-hazards regression analysis was
adjusted for demographics, i.e., sex and age. Model 2 was additionally adjusted for transplantation
related variables, namely primary renal disease, BMI, donor age, time from transplantation to follow-up,
eGFR and proteinuria. In the next models, baseline characteristics which were cross-sectionally
associated with 24-h urinary oxalate excretion were subsequently included, and potential confounding
of urinary thiosulfate was investigated due to its role in the anion transporters in the proximal renal
tubuli (Model 3) [33]. In addition, we also looked for lactate dehydrogenase (LDH) because of its
importance in the conversion of glyoxylate (Model 4) [34], for 24-h urinary pH because of its influence
on the reaction of oxalate with calcium (Model 5) [35], for fibroblast growth factor 23 (FGF23) because of
the relationship with gastrointestinal calcium absorption and oxalate bioavailability [36,37] (Model 6),
and for fruits and vegetables as main dietary sources of oxalate [38–40] (Model 7). To allow for detection
of a potential threshold effect, which was found in an earlier study on urinary oxalate excretion and
CKD [14], Cox regression analyses were also performed according to sex-stratified tertiles with the
first tertile as reference.
Spline regression were created to visualize the association of 24-h urinary oxalate excretion for
outcomes, for which we consistently found significant associations. Nonlinearity was tested by using
the likelihood ratio test, comparing models with linear or linear and cubic spline terms. Restricted cubic
splines were knotted at the minimum, median and maximum. The splines were adjusted according to
Model 6 of the primary prospective analyses.
Sensitivity Analyses
Several sensitivity analyses were performed to examine the robustness of the associations between
24-h urinary oxalate excretion and outcomes. For that purpose, we reanalyzed the data excluding
subjects with potential inadequate 24-h urine collection (i.e., overcollection or undercollection), which
was defined as the upper and lower 2.5% of the difference between the estimated and measured volume
of a subject’s 24-h urine sample. The following formula was used to calculate the estimated 24-h urine
volume: 14 ((urine creatinine) * (24-h urine volume)/(serum creatinine)), where creatinine clearance was
estimated using the Cockcroft-Gault Formula [41,42]. These analyses were analogous to Model 6 of the
primary prospective analyses.
Furthermore, we performed competing risk analyses of outcomes of interest with all-cause
mortality as competing event according to Fine and Gray [43]. For that purpose, we performed
multivariable Cox regression analyses analogously to Model 6 of the primary prospective analyses.
3. Results
3.1. Baseline Characteristics
In total 683 KTR were included in the analyses (mean age 53 ± 13, 43% female, 99.6% Caucasian
ethnicity). Median urinary oxalate excretion was 505 (IQR, 347–732) µmol/24-h in women and 519
(IQR, 396–736) µmol/24-h in men (p = 0.08). Forty-four percent of the patients were above the range of
clinical hyperoxaluria of ≤455 µmol/24-h. All 227 study subjects in tertile 3 were above the clinical
cutoff point for hyperoxaluria, and all 227 subjects in tertile 1 were below the clinical cutoff point.
Mean eGFR was 52 ± 20 mL/min/1.73 m2. Additional baseline characteristics and analyses are shown
overall and by sex-stratified tertiles of 24-h urinary oxalate excretion in Table 1.
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Table 1. Baseline characteristics of the overall population, and by sex-stratified tertiles of 24-h urinary oxalate excretion. a
Baseline Characteristics Overall KTR
n = 683
Sex-Stratified Groups of 24-h Urinary Oxalate Excretion
p
♀≤ 390; ♂≤ 431 ♀391–633; ♂432–632 ♀≥ 633; ♂≥ 632
µmol/24-h µmol/24-h µmol/24-h
Oxalate
Oxalate in 24-h urine, µmol b 514 (378–732) 339 (278–278) 514 (461–563) 882 (732–1137) —
Demographics
Age, years 53 ± 13 54 ± 13 53 ± 12 51 ± 13 0.04
Sex (female), n (%) 295 (43) 98 (43) 99 (43) 98 (43) 1.00
Ethnicity (Caucasian), n (%) 680 (99.6) 226 (99.6) 228 (99.6) 226 (99.6) 1.00
Body composition
BSA, m2 1.94 ± 0.22 1.92 ± 0.21 1.98 ± 0.21 1.94 ± 0.23 0.05
BMI, kg/m2 26.6 ± 4.8 26.3 ± 4.8 27.0 ± 4.6 26.6 ± 4.8 0.34
Waist circumference, cm 98 (89–108) 97 (89–105) 100 (90–110) 96 (87–106) 0.02
Lifestyle
Current smoker, n (%) 81 (12) 42 (19) 19 (9) 20 (9) 0.001
Alcohol consumption 0.30
None, n (%) 22 (3) 6 (3) 8 (4) 8 (4)
0–10 g/day, n (%) 426 (62) 144 (64) 146 (64) 136 (60)
10–30 g/day, n (%) 137 (20) 44 (19) 44 (19) 49 (22)
>30 g/dag, n (%) 37 (5) 10 (4) 12 (5) 15 (7)
SQUASH-score 5070 (2040–7800) 4440 (1680–7240) 5400 (2323–8475) 5580 (2280–7980) 0.10
Cardiovascular
History of CV disease, n (%) 295 (50) 92 (41) 103 (45) 100 (44) 0.72
SBP, mmHg 136 ± 18 137 ± 17 136 ± 18 135 ± 18 0.42
MAP, mmHg (calculated) 100 ± 12 101 ± 11 100 ± 12 100 ± 13 0.73
LDL cholesterol, mmol/L 3.0 ± 0.9 3.1 ± 0.9 3.0 ± 0.9 2.9 ± 0.9 0.54
Triglycerides, mmol/L 1.7 (1.2–2.3) 1.7 (1.3–2.3) 1.6 (1.2–2.4) 1.7 (1.2–2.2) 0.69
Glucose homeostasis
Diabetes mellitus, n (%) 162 (24) 52 (23) 58 (25) 53 (23) 0.78
Plasma glucose, mmol/L 5.3 (4.8–6.0) 5.3 (4.8–5.9) 5.2 (4.8–6.2) 5.3 (4.7–6.1) 0.85
Diet
Av. energy intake, kCal/day 2092 (1720–2536) 2045 (1705–2479) 2104 (1735–2557) 2171 (1759–2589) 0.45
Av. daily fat intake, g/d c 84 (65–106) 80 (63–101) 85 (66–106) 86 (64–110) 0.31
Av. daily protein intake, g/d c 81 (67–95) 80 (65–95) 81 (66–95) 81 (68–95) 0.82
Glycine, mg/d c 3276 ± 806 3228 ± 805 3261 ± 817 3337 ± 794 0.38
Ascorbic acid, mg/d c 84 (60–118) 70 (53–101) 82 (60–114) 103 (73–138) <0.001
Vegetables, g/d 93 ± 58 94 ± 53 90 ± 53 96 ± 66 0.54
Fruits, g/d 123 (65–232) 111 (50–226) 121 (64–228) 165 (81–247) 0.001
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Table 1. Cont.
Baseline Characteristics Overall KTR
n = 683
Sex-Stratified Groups of 24-h Urinary Oxalate Excretion
p
♀≤ 390; ♂≤ 431 ♀391–633; ♂432–632 ♀≥ 633; ♂≥ 632
µmol/24-h µmol/24-h µmol/24-h
Transplantation characteristics
Age donor, years 43 ± 15 43 ± 15 43 ± 16 43 ± 16 0.85
Sex donor (female), n (%) 322 (47) 108 (49) 99 (44) 15 (52) 0.24
Donor type (living), n (%) 231 (34) 67 (30) 81 (35) 83 (37) 0.24
Serum markers
Venous pCO2, kPa 5.9 ± 0.8 5.9 ± 0.9 5.9 ± 0.8 5.8 ± 0.8 0.53
Leukocyte count, per 109/L 8.2 ± 2.7 8.3 ± 2.6 8.1 ± 2.8 8.1 ± 2.6 0.52
HsCRP, mg/L 1.6 (0.7–4.6) 1.6 (0.8–4.4) 2.0 (0.8–5.3) 1.4 (0.6–3.8) 0.04
Hemoglobin, mmol/L 8.2 ± 1.1 8.1 ± 1.1 8.2 ± 1.1 8.3 ± 1.1 0.11
FGF-23 61 (43–99) 63 (43–107) 61 (42–98) 61 (45–97) 0.66
LDH, U/L 198 (170–232) 195 (169–232) 203 (174–238) 196 (170–223) 0.35
Vitamin B6, nmol/L 29 (18–29) 27 (16–47) 26 (15–44) 36 (22–57) <0.001
Renal allograft function
Creatinine, µmol/L 125 (100–160) 126 (99–164) 126 (101–164) 122 (100–157) 0.66
eGFR, mL/min/1.73 m2 52 ± 20 51 ± 20 52 ± 20 54 ± 20 0.26
Serum cystatin C, mg/L 1.7 (1.3–2.2) 1.7 (1.3–2.5) 1.7 (1.3–2.2) 1.6 (1.3–2.1) 0.25
Proteinuria ≥ 0.5 g/24-h, n (%) 152 (22) 49 (22) 49 (21) 54 (24) 0.59
24-h urine
pH 6.0 ± 0.5 6.0 ± 0.5 6.0 ± 0.5 6.1 ± 0.5 0.48
UUN excretion, mmol 389 ± 114 349 ± 100 407 ± 111 412 ± 1 <0.001
Phosphate excretion, mmol 25 ± 9 22 ± 8 25 ± 8 27 ± 9 <0.001
Thiosulfate excretion, µmol 7.0 (3.9–12.0) 6.7 (3.7–11.0) 6.9 (4.2–12.5) 7.5 (3.8–12.6) 0.57
Protein excretion, mg 196 (15–367) 163 (15–281) 221 (15–380) 200 (15–417) 0.10
Abbreviations: ♀, female; ♂, male; KTR, kidney transplant recipients; n, number; β, standardized beta; BSA, body surface area; BMI, body mass index; SQUASH, Short Questionnaire to
Assess Health-enhancing physical activity; SBP, systolic blood pressure; MAP, mean arterial pressure; LDL, low density lipoprotein; Av., average; hs-CRP, high sensitivity C-reactive protein;
LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; UUN, urinary urea nitrogen; FGF-23, fibroblast growth factor 23. a Normally distributed variables are expressed as
mean ± standard deviation (SD), skewed data as medians (25th–75th inter quartile range (IQR)), categorical data is given as number and percentage, n, (%). Analyses of difference in
baseline characteristics across sex-stratified tertiles of 24-h urinary oxalate excretion were tested by ANOVA for normally distributed continuous variables; Kruskal-Wallis for skewed
continuous variables; χ2 test for categorical data. b To convert oxalate in µmol/24-h to mg/24-h, multiply by 0.088. c Adjusted for energy intake.
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3.2. Cross-Sectional Analysis
We found that age (p = 0.04), current smoking status (p = 0.01), and cystatin C (p = 0.03)
were inversely associated with 24-h urinary oxalate excretion, whereas plasma glucose (p = 0.01),
ascorbic acid (p < 0.001), fruit consumption (p < 0.001), vitamin B6 (p < 0.001), urinary urea nitrogen
excretion (p < 0.001), and phosphate excretion (p < 0.001) were positively associated with 24-h urinary
oxalate excretion.
3.3. Prospective Analyses
GF and mortality were recorded during a follow-up of 5.3 years (IQR, 4.5–6.0). During follow-up,
83 (12%) patients developed GF, 55 (9%) patients developed PTDM and 149 (22%) patients died, of
which 59 deaths (40%) were due to cardiovascular causes, 41 deaths (28%) due to infectious causes, 26
deaths (17%) due to malignancies and 23 deaths (15%) due to miscellaneous causes (Table 2).
Table 2. Association of baseline characteristics with 24-h urinary oxalate excretion. a
Baseline Characteristics β p
Demographics
Age, years −0.08 0.04
Lifestyle
Current smoker −0.11 0.01
Plasma glucose, mmol/L 0.10 0.01
Diet
Ascorbic acid, mg/d C 0.24 <0.001
Fruits, g/d 0.16 <0.001
Blood markers
Vitamin B6 in blood, nmol/L 0.20 <0.001
Renal allograft function
Cystatin C, blood, mg/L −0.16 0.03
24-h Urine
UUN excretion, mmol 0.24 <0.001
Phosphate excretion, mmol 0.25 <0.001
a Multivariate linear regression, adjusted for age, sex and eGFR.
3.3.1. GF, PTDM, Cardiovascular Mortality, Mortality due to Malignancies, and
Miscellaneous Mortality
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with GF is
shown in Figure 1A (p = 0.20, p for trend 0.08). Results of multivariate Cox regression analyses did not
show a consistent association of 24-h urinary oxalate excretion with GF (HR 0.71, 95% CI 0.53–0.98)
(Table 3). Uni- and multivariate analyses of the associations of 24-h urinary oxalate excretion and
potential confounders with GF are shown in Table S1.
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with PTDM is
shown in Figure 1B (p = 0.24, p for trend 0.37). Results of multivariate Cox regression analyses showed
no association of 24-h urinary oxalate excretion with PTDM (HR 0.95, 95% CI 0.71–1.27) (Table 3).
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with
cardiovascular mortality is shown in Figure 1C (p = 0.08, p for trend 0.08). Results of multivariate
Cox regression analyses showed cardiovascular mortality is not associated with 24-h urinary oxalate
excretion (HR 0.78, 95% CI 0.56–1.10) (Table 4).
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Figure 1. (A) Graft failure, (B) PTDM, (C) cardiovascular mortality, (D) death due to malignancy, (E) 
miscellaneous mortality (F) all-cause mortality, and (G) death due to infection according to 
sex-stratified tertiles of 24-hour urinary oxalate excretion over approximately 7 years of follow-up.  
Figure 1. (A) Graft failure, (B) PTDM, (C) cardiovascular mortality, (D) death due to malignancy,
(E) miscellaneous mortality (F) all-cause mortality, and (G) death due to infection according to
sex-stratified tertiles of 24-hour urinary oxalate excretion over approximately 7 years of follow-up.
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Table 3. Association of 24-h urine oxalate excretion with graft failure and PTDM.
Continuous, Tertiles
per 1–SD Tertile 1 Tertile 2 Tertile 3
HR 95%CI Ref HR 95% CI HR 95% CI
Graft Failure
Model 1 0.80 0.64–1.00 1.00 0.82 0.50–1.36 0.58 0.33–1.00
Model 2 0.78 0.61–1.02 1.00 0.77 0.45–1.32 0.61 0.35–1.08
Model 3 0.72 0.54–0.94 1.00 0.68 0.39–1.17 0.48 0.26–0.86
Model 4 0.71 0.53–0.93 1.00 0.68 0.40–1.18 0.45 0.24–0.82
Model 5 0.71 0.53–0.93 1.00 0.66 0.38–1.15 0.43 0.23–0.80
Model 6 0.71 0.53–0.98 1.00 0.69 0.39–1.20 0.44 0.24–0.83
Model 7 0.75 0.56–1.00 1.00 0.70 0.40–1.25 0.48 0.19–0.77
PTDM
Model 1 0.93 0.71–1.22 1.00 1.27 0.68–2.37 0.71 0.34–1.46
Model 2 0.91 0.69–1.23 1.00 1.23 0.66–2.32 0.68 0.33–1.41
Model 3 0.91 0.68–1.22 1.00 1.32 0.70–2.50 0.61 0.28–1.33
Model 4 0.94 0.70–1.25 1.00 1.39 0.73–2.68 0.66 0.30–1.44
Model 5 0.95 0.73–1.27 1.00 1.50 0.77–2.91 0.71 0.32–1.57
Model 6 0.95 0.71–1.27 1.00 1.50 0.77–2.91 0.76 0.34–1.73
Model 7 0.99 0.73–1.33 1.00 1.45 0.74–2.83 0.75 0.34–1.69
Multivariate Cox regression were performed for the association of 24-h urinary oxalate excretion with graft failure
and PTDM. Model 1: age and sex adjusted. Model 2: Model 1 + adjustment for BMI, primary renal disease, donor
age, transplant vintage, eGFR, and proteinuria. Model 3: Model 2 + adjustment for thiosulfate in 24-h urine. Model
4: Model 3 + adjustment for LDH in blood. Model 5: Model 4 + adjustment for pH of 24-h urine. Model 6: Model 5
+ adjustment for FGF23. Model 7: Model 6 + adjustment for fruit and vegetables intake.
Table 4. Association of 24-h urine oxalate excretion with all-cause and cardiovascular mortality.
Continuous, Tertiles
per 1–SD Tertile 1 Tertile 2 Tertile 3
HR 95% CI Ref HR 95% CI HR 95% CI
All-cause mortality
Model 1 0.83 0.70–0.98 1.00 0.86 0.59–1.25 0.72 0.48–1.74
Model 2 0.81 0.67–0.97 1.00 0.84 0.57–1.23 0.73 0.48–1.14
Model 3 0.76 0.62–0.93 1.00 0.85 0.58–1.25 0.56 0.35–0.88
Model 4 0.76 0.62–0.92 1.00 0.80 0.54–1.18 0.53 0.34–0.83
Model 5 0.77 0.63–0.94 1.00 0.79 0.53–1.17 0.54 0.34–0.86
Model 6 0.77 0.63–0.94 1.00 0.75 0.50–1.13 0.55 0.34–0.86
Model 7 0.83 0.68–1.03 1.00 0.74 0.48–1.15 0.67 0.41–1.11
Cardiovascular mortality
Model 1 0.90 0.69–1.19 1.00 0.90 0.48–1.69 1.09 0.59–2.00
Model 2 0.87 0.65–1.17 1.00 0.84 0.44–1.62 1.11 0.59–2.08
Model 3 0.78 0.56–1.09 1.00 0.87 0.45–1.69 0.81 0.40–1.63
Model 4 0.77 0.56–1.08 1.00 0.81 0.42–1.57 0.75 0.37–1.53
Model 5 0.79 0.57–1.09 1.00 0.82 0.42–1.59 0.78 0.38–1.57
Model 6 0.78 0.56–1.10 1.00 0.82 0.41–1.62 0.77 0.37–1.59
Model 7 0.79 0.55–1.13 1.00 0.80 0.39–1.66 0.75 0.33–1.70
Multivariate Cox regression were performed for the association of 24-h urinary oxalate excretion with all-cause and
cardiovascular mortality. Model 1: age and sex adjusted. Model 2: Model 1 + adjustment for BMI, primary renal
disease, donor age, transplant vintage, eGFR, and proteinuria. Model 3: Model 2 + adjustment for thiosulfate in
24-h urine. Model 4: Model 3 + adjustment for LDH in blood. Model 5: Model 4 + adjustment for pH of 24-h urine.
Model 6: Model 5 + adjustment for FGF23. Model 7: Model 6 + adjustment for fruit and vegetables intake.
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with death
due to malignancy is shown in Figure 1D (p = 0.51, p for trend 0.29). Results of multivariate Cox
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regression analyses showed mortality due to malignancies is not associated with 24-h urinary oxalate
excretion (HR 1.14, 95% CI 0.73–1.77) (Table 5).
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion miscellaneous
mortality is shown in Figure 1E (p = 0.11, p for trend 0.10). Results of multivariate Cox regression
analyses showed miscellaneous death causes are not associated with 24-h urinary oxalate excretion
(HR 0.75, 95% CI 0.45–1.26) (Table 5).
Table 5. Association of 24-h urine oxalate excretion with death due to infection, malignancy and
other causes.
Continuous, Tertiles
per 1–SD Tertile 1 Tertile 2 Tertile 3
HR 95% CI Ref HR 95% CI HR 95% CI
Death due to infection
Model 1 0.67 0.49–0.92 1.00 0.75 0.39–1.47 0.33 0.13–0.83
Model 2 0.58 0.40–0.83 1.00 0.75 0.38–1.49 0.31 0.12–0.79
Model 3 0.54 0.36–0.81 1.00 0.70 0.35–1.40 0.25 0.09–0.68
Model 4 0.56 0.38–0.82 1.00 0.65 0.32–1.30 0.23 0.09–0.63
Model 5 0.57 0.38–0.84 1.00 0.65 0.32–1.32 0.24 0.09–0.66
Model 6 0.56 0.38–0.83 1.00 0.62 0.31–1.26 0.25 0.09–0.67
Model 7 0.58 0.38–0.88 1.00 0.57 0.27–1.21 0.30 0.11–0.83
Death due to malignancy
Model 1 1.01 0.69–1.50 1.00 1.31 0.54–3.17 0.78 0.28–2.20
Model 2 0.98 0.65–1.47 1.00 1.31 0.54–3.18 0.74 0.26–2.09
Model 3 1.02 0.68–1.53 1.00 1.50 0.60–3.77 0.84 0.29–2.45
Model 4 1.03 0.68–1.55 1.00 1.56 0.62–3.94 0.88 0.30–2.59
Model 5 1.08 0.71–1.62 1.00 1.44 0.56–3.71 0.95 0.32–2.81
Model 6 1.10 0.71–1.71 1.00 1.24 0.45–3.41 1.01 0.33–3.07
Model 7 1.14 0.73–1.77 1.00 1.08 0.36–3.8 1.18 0.37–3.71
Death due to other causes
Model 1 0.76 0.48–1.21 1.00 0.63 0.23–1.71 070 26–1.89
Model 2 0.82 0.51–1.35 1.00 0.53 0.19–1.47 0.62 0.22–1.74
Model 3 0.77 0.45–1.29 1.00 0.59 0.21–1.65 0.43 0.13–1.41
Model 4 0.76 0.45–1.27 1.00 0.53 0.19–1.51 0.39 0.12–1.29
Model 5 0.76 0.46–1.28 1.00 0.53 0.19–1.51 0.39 0.12–1.29
Model 6 0.75 0.45–1.26 1.00 0.46 0.16–1.35 0.36 0.11–1.20
Model 7 0.96 0.56–1.63 1.00 0.64 0.19–2.19 0.75 0.20–2.74
Multivariate Cox regression were performed for the association of 24-h urinary oxalate excretion with death due
to infection, malignancy and other causes. Model 1: age and sex adjusted. Model 2: Model 1 + adjustment for
BMI, primary renal disease, donor age, transplant vintage, eGFR, and proteinuria. Model 3: Model 2 + adjustment
for thiosulfate in 24-h urine. Model 4: Model 3 + adjustment for LDH in blood. Model 5: Model 4 + adjustment
for pH of 24-h urine. Model 6: Model 5 + adjustment for FGF23. Model 7: Model 6 + adjustment for fruit and
vegetables intake.
3.3.2. All-Cause and Infectious Mortality
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with all-cause
mortality is shown in Figure 1F (p = 0.06, p for trend 0.02). Results of multivariate Cox regression
analyses showed, however, that all-cause mortality is independently associated with 24-h urinary
oxalate excretion (HR 0.77, 95% CI 0.63–0.94) (Table 4). Uni- and multivariate analyses of the associations
of 24-h urinary oxalate excretion and potential confounders with all-cause mortality are shown in Table
S2. The association of 24-h urinary oxalate excretion with all-cause mortality demonstrated a nonlinear
relationship, as shown by a restricted cubic spline (Figure 2A).
A Kaplan-Meier curve for the association of tertiles of 24-h urinary oxalate excretion with infectious
mortality is shown in Figure 1G (p = 0.03, p for trend 0.008). Results of multivariate Cox regression
analyses showed infectious mortality was independently associated with 24-h urinary oxalate excretion
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(HR 0.58, 95% CI 0.38–0.83) (Table 5). The association between 24-h urinary oxalate excretion and







Figure 2. Adjusted association of standardized log 24–hour urinary oxalate excretion with (A) all-cause
mortality, and (B) infectious mortality, based on restricted cubic spline regression, fitted with Model 6.
The black line in the graph represents the HR, 95% CI is shown and the gray area.
3.4. Sensitivity Analyses
When we restricted the analyses to subjects with no potential over or undercollection of 24-h urine
samples based on differences in expected and observed 24-h urinary creatinine excretions (n = 650),
generally similar results were found for GF (HR 0.74, 95% CI 0.55–0.99), PTDM (HR 0.93, 95% CI
0.69–1.26), cardiovascular mortality (HR 0.68, 95% CI 0.47–0.98), mortality due to malignancies (HR
1.10, 95% CI 0.70–1.72), mortality due to miscellaneous causes (HR 0.71, 95% CI 0.41–1.24), all-cause
mortality (HR 0.74; 95% CI 0.59–0.92), and infectious mortality (HR 0.58, 95% CI 0.37–0.89).
When competing risk analyses were performed, generally similar results were found for PTDM
(HR 1.15, 95% CI 0.91–1.48), cardiovascular mortality (HR 0.82, 95% CI 0.55–1.23), mortality due to
malignancies (HR 1.16, 95% CI 0.69–1.95), mortality due to miscellaneous causes (HR 0.84, 95% CI
0.54–1.31), and infectious mortality (HR 0.61, 95% CI 0.45–0.85). The risk of GF was not consistently
significant (HR 1.14, 95% CI 0.64–2.26).
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4. Discussion
In KTR, median excretion of 24-h oxalate was higher than the clinical cut-off point for hyperoxaluria.
No association of 24-h urinary oxalate excretion was found with GF, PTDM, cardiovascular mortality,
or mortality due to malignancy or miscellaneous causes, but an independent, inverse association with
all-cause mortality and infectious mortality was found. There was respectively a 23% and 44% decrease
in hazard ratio per standard deviation increase of 24-h urinary oxalate excretion. The associations
remained materially unchanged after adjusting for potential confounders. The association with all-cause
and infectious mortality remained materially unchanged after performing sensitivity analyses.
A single-centered prospective study had previously already found an elevated plasma oxalate
level in KTR [44]. However, no previous study has provided data on oxalate excretion. The elevated
urinary oxalate excretion reflects one of the major findings of this study, being that 44% of the stable
KTR are within the clinical range of hyperoxaluria.
To the best of our knowledge, there have not been any previous studies investigating the association
of urinary oxalate with GF, PTDM and (cause-specific) mortality in stable KTR. However, a recent
study of Waikar et al. with CKD patients stage 2 to 4 found 24-h urinary oxalate excretion to be
positively associated with all-cause mortality [14]. With regards to the study of Waikar et al., their
first four quintiles can be considered to be below the range of hyperoxaluria of 455µmol/24-h, whereas
in our population, only the first tertile can be considered normal with regard to urinary oxalate
excretion. This, in part, might explain the difference in association of urinary oxalate excretion with the
outcome variables.
The difference between Waikar et al.’s and our study cannot be explained by a higher BMI or
diabetes contributing to hyperoxaluria through higher effective renal plasma flow and glomerular
hyperfiltration in the Waikar et al. population (respectively, BMI of 32.1 ± 7.7 and 26.6 ± 4.8 and
diabetes in 48.9% and 24% of the population) [45]. Low density lipoprotein (LDL) profile was not
published in the Waikar et al. report, therefore, difference in oxalate excretion through dyslipidemia
cannot be determined [46]. In both studies, the urinary samples were stored at −80 ◦C. Storage at this
temperature can lead to underestimation of oxalate levels through calcium oxalate precipitation [14].
Since the difference of storage time of the samples until measurement is not known, we cannot
exclude this as a potential clarification of the found difference. Additionally, spontaneous oxalate
generation over the course of the storage might have increased the sample oxalate levels in either
studies. Another hypothesis for the interesting difference in 24-h urinary oxalate excretion between
the study of Waikar et al. might be found in the possible absence of Oxalobacter formigenes in the
gut microbiome. KTR have been exposed to antimicrobial prophylactic therapies to lower the risk
of opportunistic infections. This greatly affects the diversity of the human microbiome and can
cause dysbiosis [47]. Dysbiosis in KTR could contribute to a decrease of O. formigenes and therefore,
increased gastrointestinal absorption of oxalate, leading to an increased oxalate serum concentration
and consequently, elevated urinary excretion.
We found no association with GF, PTDM, mortality due to malignancies, nor mortality due to
miscellaneous causes. The results of the proportional hazards models show that the inverse overall
association with mortality is mainly driven by infectious mortality. We hypothesized that because 24-h
urinary oxalate excretion was positively associated with ascorbic acid, which is inversely associated
with overall mortality in RTR through reducing inflammation, an increase in oxalate might contribute
to a lower infectious mortality [48]. However, the exact mechanism behind the association of 24-h
urinary oxalate excretion with infectious mortality remains to be further investigated, since to our
knowledge, there are no studies available showing a potential theoretical explanation.
The strength of this study lays in its prospective design, with a large cohort of stable KTR who
were closely monitored according to standardized protocols and continuous surveillance system
according to the American Society of Transplantation without loss due to follow-up during a median
follow-up of 5.4 years for (specific cause) mortality. The KTR were extensively phenotyped at baseline
measurement, providing a broad array of potential confounders to adjust for. The inclusion of the
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FFQ gives the possibility to assess the associations with dietary intake, rather than just the urinary
excretion. Furthermore, urine was collected as 24-h collecting samples, according to a previously
described strict protocol, which eliminates possible daily variances in fluid balance and excretion to
give a more accurate excretion estimate. Additionally, potential over- or undercollection of the 24-h
urine samples was accounted for by means of sensitivity analyses, which showed that the results
remained materially unchanged after restricting the study population as described previously.
However, we also acknowledge limitations of the current study. First, we were unable to adjust
our results for socioeconomic status at baseline. Next, although the FFQ and SQUASH are validated
questionnaires, they are self-reported, which may lead to possible over or underreporting of dietary
intake and physical activity. We also acknowledge that our population consists almost entirely
of Caucasian ethnicity, therefore, our results call for caution to extrapolate our results to different
populations with regard to ethnicity. Finally, data on nephrolithiasis was not documented; therefore,
we were unable to assess the association of urinary oxalate with the outcome nephrolithiasis, which
remains a rather overlooked topic in KTR. Nevertheless, our results show for the first time a high
prevalence of hyperoxaluria in the post-kidney transplant setting, thus emphasizing the need for future
studies in which such analyses are performed. Additionally, because the study of the microbiome
was beyond the scope of the current study, the hypothesized mechanism of increased gastrointestinal
absorption of oxalate to explain the observed levels of hyperoxaluria cannot be further confirmed.
In conclusion, in stable KTR, 24-h urinary oxalate excretion is quantitatively higher than in the
general population. Forty-four percent of the current study population showed urinary oxalate levels
above the range of clinical hyperoxaluria. This hyperoxaluria might suggest a role of dysbiosis by
leading to diminished O. formigenes and therefore, higher oxalate absorption and excretion in the
current study population. Twenty-four-hour urinary oxalate excretion was not associated with risk of
graft failure, post-transplant diabetes mellitus, cardiovascular mortality, mortality due to malignancies,
nor death from miscellaneous causes. However, a consistent and independent inverse association was
found with infectious mortality. Our data encourages further studies to validate our findings on the
associations of oxalate with long-term outcomes in KTR. Future studies are warranted to investigate
specific causes of death and the effect of hyperoxaluria post-kidney transplantation.
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